金迪克1月29日获融资买入790.48万元，融资余额3841.06万元

Group 1 - The core viewpoint of the news is that Jindike's stock experienced a decline of 5.81% on January 29, with a trading volume of 128 million yuan, indicating market volatility and investor sentiment [1] - As of January 29, Jindike's financing balance totaled 38.41 million yuan, accounting for 1.43% of its market capitalization, which is above the 80th percentile of the past year, suggesting a high level of financing activity [1] - Jindike's main business focuses on the research, production, and sales of human vaccines, with vaccine products constituting 100% of its revenue [1] Group 2 - As of September 30, Jindike had 4,319 shareholders, a decrease of 4.55% from the previous period, while the average circulating shares per person increased by 4.77% to 28,525 shares [2] - For the period from January to September 2025, Jindike reported operating revenue of 74.66 million yuan, a year-on-year increase of 91.93%, but a net profit attributable to shareholders of -86.47 million yuan, a decrease of 61.74% year-on-year [2] - Since its A-share listing, Jindike has distributed a total of 61.60 million yuan in dividends, with 17.60 million yuan distributed over the past three years [2]